Research Analysts Offer Predictions for BDRX Q1 Earnings

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for shares of Biodexa Pharmaceuticals in a report released on Monday, June 29th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of $0.00 for the quarter. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.00 EPS.

BDRX has been the subject of a number of other research reports. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX stock opened at $2.91 on Wednesday. The company’s 50 day moving average is $3.36 and its 200 day moving average is $6.75. Biodexa Pharmaceuticals has a 1-year low of $2.45 and a 1-year high of $66.50.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.